Related by context. All words. (Click for frequent words.) 77 dosing regimens 76 dosage regimens 74 dose cohorts 73 dose regimen 73 dosing schedules 72 ritonavir boosted 72 ascending doses 71 active comparator 70 placebo controlled studies 70 oral rivaroxaban 69 abacavir lamivudine 69 placebo controlled clinical trials 69 mycophenolate mofetil 68 teriflunomide 68 ascending dose 68 dosing intervals 68 docetaxel chemotherapy 68 dexamethasone Decadron 68 FOLFIRI 67 dose escalation 67 administered subcutaneously 67 pharmacodynamics PD 67 PREZISTA r 67 irbesartan 67 dosed orally 67 dosage regimen 67 bendamustine 67 APTIVUS 67 #mg/m# [002] 67 immunomodulatory therapy 67 pegylated interferon alfa 2a 67 boosted protease inhibitor 67 chlorambucil 67 efavirenz EFV 66 KAPIDEX 66 dose cohort 66 MIRCERA 66 tenofovir emtricitabine 66 nab paclitaxel 66 mg dose 66 peginterferon alfa 2a 66 dosing cohorts 66 dosing regimen 66 dose cytarabine 66 analgesic efficacy 66 protease inhibitor PI 66 relapsed MM 66 #mg QD [001] 66 certolizumab 66 chemotherapeutic regimens 66 interferon alfa 2b 66 dose titration 66 forodesine 66 galiximab 66 #mg doses [002] 66 mg BID 66 Pegasys ® 66 tapentadol ER 66 maximally tolerated dose 66 carboplatin paclitaxel 66 mg QD 66 insulin detemir 65 LEXIVA r 65 placebo controlled trials 65 subcutaneous injections 65 tolerability profiles 65 cilostazol 65 subcutaneously administered 65 APTIVUS r 65 visilizumab 65 melphalan prednisone 65 Peg IFN 65 docetaxel Taxotere ® 65 stavudine d4T 65 antiretroviral regimen 65 fluvastatin 65 darunavir ritonavir 65 Pegasys peginterferon alfa 2a 65 SCH # 65 virological failure 65 intermittent dosing 65 chlorthalidone 65 dose escalation trial 65 mg/m2 dose 65 dose dose escalation 65 blinded randomized placebo controlled 65 nucleoside reverse transcriptase inhibitor 65 tolerability profile 65 intravenous dosing 65 lopinavir r 65 intravenous IV infusion 65 CANCIDAS 65 peginterferon alfa 2b 65 weekly subcutaneous injections 65 double blinded placebo 65 bolus dose 65 DAPT 64 subcutaneous SC 64 mcg doses 64 tenofovir Viread 64 DU #b 64 viral kinetic 64 Teriflunomide 64 Tarceva TM 64 subcutaneous dosing 64 epoetin alfa 64 placebo controlled clinical 64 pharmacokinetic parameters 64 vicriviroc 64 mitoxantrone 64 trials RCTs 64 monotherapy 64 dosing cohort 64 FOLPI 64 lamivudine 64 tolerability 64 dalteparin 64 pharmacodynamic profile 64 virologic failure 64 genotypic resistance 64 ibandronate 64 HCV SPRINT 64 unfractionated heparin 64 adalimumab 64 ACTEMRA TM 64 rilpivirine 64 ABC/3TC 64 dose dexamethasone 64 #mg q8h 64 subcutaneous doses 64 ritonavir boosted atazanavir 64 Panzem R NCD 64 mg kg dose 64 cilengitide 64 lapatinib Tykerb 64 primary hypercholesterolemia 64 HAART regimen 64 atazanavir ritonavir 64 LPV r 64 μg dose 63 decitabine 63 randomized controlled clinical trials 63 alfa 2a 63 pegylated interferon alfa 63 mesalamine granules 63 diuretic chlorthalidone 63 #mg/m# [001] 63 gemcitabine carboplatin 63 valsartan amlodipine 63 #mg dose [001] 63 pomalidomide 63 q8h 63 antiviral efficacy 63 daunorubicin 63 NATRECOR R 63 docetaxel Taxotere R 63 pegfilgrastim 63 secondary efficacy endpoints 63 subcutaneous formulation 63 HCV RESPOND 2 63 NATRECOR ® 63 atazanavir 63 nilotinib 63 DMARD therapy 63 bicifadine 63 pharmacokinetic profiles 63 mg RDEA# 63 azathioprine 63 mcg kg 63 vandetanib 63 doxorubicin cyclophosphamide 63 clopidogrel Plavix 63 plus ribavirin 63 PREZISTA rtv 63 RRMS patients 63 comparator arm 63 salmeterol fluticasone 63 desvenlafaxine succinate 63 standard chemotherapy regimens 63 nevirapine Viramune 63 tolterodine ER 63 infusional 63 pharmacodynamic properties 63 multicenter randomized placebo controlled 63 TDF FTC 63 fluticasone furoate 63 3TC lamivudine Epivir 63 paricalcitol 63 Bezielle 63 flutamide 63 NRTI 63 q#h 63 temsirolimus 63 TMC# [001] 63 inhibitor RG# 63 tipranavir 63 tolerated dose MTD 63 continuous intravenous infusion 63 double blinded randomized 63 antiepileptics 63 safety tolerability pharmacokinetics 63 lipid lowering agents 63 INVEGA ® 63 posaconazole 63 nelfinavir 63 ARCOXIA 63 pharmacokinetics PK 63 metformin sulfonylurea 63 rizatriptan 63 azacitidine 63 dose colchicine 63 mg/m2 63 venlafaxine Effexor 63 receptor tyrosine kinase inhibitor 63 dirucotide MBP# 63 timepoints 63 subcutaneous dose 63 IFN alfa 63 pertuzumab 63 RLAI 63 phase Ib 62 superficial bladder cancer 62 piperacillin tazobactam 62 randomized #:#:# 62 ISENTRESS 62 insulin degludec 62 VELCADE melphalan 62 pyridostigmine 62 divalproex sodium 62 mcg dose 62 tacrolimus ointment 62 NRTIs 62 pegylated interferons 62 zidovudine lamivudine 62 sitagliptin 62 #mg BID [003] 62 sorafenib Nexavar 62 mcg BID 62 HAART regimens 62 nonrandomized 62 glatiramer acetate 62 aspirin clopidogrel 62 pegylated interferon alpha 62 chemotherapy docetaxel 62 mg doses 62 mapatumumab 62 randomized multicenter trial 62 direct thrombin inhibitors 62 IV bolus 62 ZOLINZA 62 platelet inhibitor 62 dose cyclophosphamide 62 risperidone Risperdal 62 octreotide LAR 62 mitomycin 62 protease inhibitors PIs 62 unfractionated heparin UFH 62 zolmitriptan 62 ziprasidone 62 antihypertensive medications 62 controlled multicenter 62 indapamide 62 plus prednisone 62 Diovan HCT 62 Phase 1b trial 62 buprenorphine naloxone 62 low dose cytarabine 62 rFVIIa 62 Tekamlo 62 mg administered orally 62 gadobutrol 62 LIALDA 62 alvespimycin 62 Pemetrexed 62 Vidaza azacitidine 62 erlotinib Tarceva ® 62 noninferiority 62 mg/m2/day 62 Dasatinib 62 pharmacologically active isomer 62 #mg/#mg 62 iniparib 62 antihypertensive drugs 62 antiepileptic drugs AEDs 62 AGILECT R 62 pioglitazone 62 dacarbazine 62 amoxicillin clavulanate 62 noninferior 62 adefovir 62 timolol 62 lopinavir ritonavir 62 epoetin beta 62 Phase Ib II 62 sorafenib Nexavar ® 62 uric acid lowering 62 therapeutic regimens 62 urate lowering 62 Copegus ribavirin 62 REMINYL ® 62 INTELENCE 62 alpha 2a 62 randomized multicenter 62 letrozole Femara 62 paclitaxel Taxol 62 Fludara 62 pharmacokinetic profile 62 perampanel 62 efficacy tolerability 62 caspofungin 62 riociguat 62 bisphosphonate therapy 62 PEGINTRON TM 62 Xelox 62 chemotherapy regimens 62 adefovir dipivoxil 62 interferon ribavirin 62 gemcitabine Gemzar 62 multicenter Phase III 62 ketorolac 62 REMICADE ® 62 tolvaptan 62 AZT zidovudine Retrovir 62 phase IIb clinical 62 Taxotere R 62 cediranib 62 FOLFOX4 62 telaprevir dosing 62 achieved statistical significance 62 LEXIVA 61 dose limiting toxicities 61 interferon alfa 61 dopamine partial agonist 61 placebo controlled Phase 61 mg m² 61 venlafaxine XR 61 CHOP chemotherapy 61 capsule formulation 61 pioglitazone Actos 61 motesanib 61 denileukin diftitox 61 safety tolerability pharmacokinetic 61 antihypertensive therapy 61 β blockers 61 azilsartan medoxomil 61 prucalopride 61 Afatinib 61 mCi kg 61 alpha blocker 61 BARACLUDE ® 61 sunitinib 61 fluticasone salmeterol 61 BENICAR HCT 61 idraparinux 61 FOLFOX 61 rt PA 61 5-FU/LV 61 oral ribavirin 61 refractory CLL 61 dosing 61 docetaxel Taxotere 61 intravenous cyclophosphamide 61 goserelin 61 NRTI backbone 61 milligram doses 61 events AEs 61 placebo controlled 61 paclitaxel cisplatin 61 montelukast 61 conventional antipsychotics 61 lamotrigine 61 fludarabine 61 blind randomized placebo 61 elotuzumab 61 8mg/kg 61 latrepirdine 61 bosentan 61 nicardipine 61 carboplatin 61 daily subcutaneous injections 61 GnRH agonists 61 dasatinib 61 topotecan 61 adjunctive placebo 61 bevacizumab Avastin ® 61 budesonide formoterol 61 mg TID 61 fosamprenavir 61 MoxDuo TM IR 61 ribavirin RBV 61 Amrubicin 61 interferon alfa 2a 61 glargine 61 Tolvaptan 61 DMARDs 61 efavirenz Sustiva 61 lacosamide 61 raloxifene Evista 61 nitazoxanide 61 paclitaxel eluting stents 61 MAGE A3 ASCI 61 inhaled iloprost 61 Darunavir 61 Traficet EN 61 antiepileptic medications 61 basal insulin 61 TNF inhibitor 61 oxycodone CR 61 alefacept 61 edoxaban 61 ULORIC 61 mixed dyslipidemia 61 esomeprazole 61 BoNTA 61 myopathy rhabdomyolysis 61 ceftriaxone 61 EURIDIS 61 placebo controlled randomized 61 Capecitabine 61 SCIg 61 ritonavir boosted protease inhibitor 61 subcutaneous PRO 61 Allovectin 7 ® 61 oral antidiabetic agents 61 saline placebo 61 dabigatran etexilate 61 CIMZIA TM 61 titrated glipizide 61 neurologic progression 61 HGS# 61 KRAS mutations occur 61 leukotriene receptor antagonist 61 blinded placebo controlled 61 JANUVIA 61 mcg QD 61 pharmacodynamics 61 antiarrhythmic drug 61 double blind placebo 61 pegylated alpha interferon 61 neratinib 61 LY# [003] 61 TMC# r 61 fulvestrant 61 subcutaneous enoxaparin 61 beta2 agonist 61 metastatic HRPC 61 tirofiban 61 abatacept 61 clomipramine 61 darunavir 61 TPV r 61 adalimumab Humira 61 MIRAPEX 61 telaprevir dosed 61 BEACOPP 61 albiglutide 61 RSD# oral 61 ribavirin therapy 61 paroxetine Paxil 61 corticosteroid dose 61 Lamictal XR 61 TEAEs 61 sustained virologic response 61 ARB telmisartan 61 VIRAMUNE XR 61 pegylated interferon alpha 2a 61 idarubicin 61 pegylated interferon 61 solifenacin 61 SUSTENNA TM 61 Femara letrozole 61 CorVue ™ 61 sunitinib malate 61 multicenter randomized 61 PegIFN RBV 61 axitinib 61 mg d 61 Epivir 61 oral prednisone 61 etanercept 61 FASLODEX 61 temozolomide 61 lamivudine 3TC 61 bupropion SR 61 Fludarabine 61 RoACTEMRA 61 pegylated liposomal doxorubicin 61 pimecrolimus cream 61 oral antidiabetic medication 61 metreleptin 61 mcg albinterferon alfa 2b 61 LMWH 61 aldosterone antagonist 61 valacyclovir 61 heavily pretreated patients 61 imatinib therapy 61 FOSRENOL ® 61 observer blinded randomized 61 PEG IFN 60 stavudine 60 dose Iluvien 60 leucovorin 60 severe renal impairment 60 Phase III randomized 60 tocilizumab 60 heavily pretreated 60 AZOR 60 Navelbine ® 60 enalapril 60 pramlintide 60 odanacatib 60 composite endpoint 60 liposomal formulation 60 octreotide 60 mg qd 60 plus prednisone prednisolone 60 LATUDA 60 mycophenolate mofetil MMF 60 dosing interval 60 Pegasys plus Copegus 60 aripiprazole Abilify 60 Platinol ® cisplatin 60 coadministration 60 lopinavir 60 ACE inhibitor ramipril 60 anti leukemic 60 nucleoside naive 60 neoadjuvant 60 Dabigatran etexilate 60 randomized Phase III 60 regimens 60 INVEGA SUSTENNA 60 ZD# [001] 60 insulin glargine 60 tecarfarin 60 Q2W 60 virologically 60 regorafenib 60 eribulin mesylate 60 pioglitazone HCl 60 Platinol 60 relapsed refractory multiple myeloma 60 vorinostat 60 xanthine oxidase inhibitor 60 6R BH4 60 peg IFN 60 oral antidiabetes drugs 60 statin monotherapy 60 CYP#D# inhibitor 60 oral diclofenac 60 primary efficacy endpoints 60 multicenter randomized double 60 cART 60 grade gliomas 60 μg doses 60 Elitek 60 biologic DMARD 60 intravesical 60 lanthanum carbonate 60 formoterol fumarate 60 #μg [002] 60 inhalations twice 60 Neulasta ® 60 evaluating tivozanib 60 events SAEs 60 insulin lispro 60 oral deforolimus 60 blind placebo 60 TMC# C# 60 pimozide 60 Engerix B 60 panitumumab Vectibix 60 oral vancomycin 60 mometasone furoate 60 elvitegravir 60 rifabutin 60 NeoRecormon 60 Phase III placebo controlled 60 ximelagatran 60 beclomethasone dipropionate 60 Melphalan 60 Platinol ® 60 CCyR 60 IIIa inhibitor 60 TYGACIL 60 MYCAMINE 60 rHuPH# 60 baminercept 60 lintuzumab SGN 60 eptifibatide 60 budesonide pMDI 60 PegIntron 60 tigecycline 60 DLTs 60 viral kinetics 60 antiplatelet agents 60 peg interferon 60 tipranavir r 60 mg q8h 60 tarenflurbil 60 placebo controlled Phase III 60 hydroxychloroquine 60 peginterferon alfa 2a Pegasys 60 #mg QD [002] 60 standard chemotherapy regimen 60 lenalidomide dexamethasone 60 pramipexole 60 Phase IIIb clinical 60 pyrazinamide 60 DMARDS 60 docetaxel 60 COMBIVIR 60 paclitaxel Taxol ® 60 Camptosar ® 60 administered concomitantly 60 candesartan cilexetil 60 statin simvastatin 60 APTIVUS R 60 ponatinib 60 Protelos 60 ATACAND 60 teriparatide 60 metaglidasen 60 thromboembolic events 60 febuxostat 60 leukotriene receptor antagonists 60 tenofovir disoproxil fumarate 60 IMC A# 60 antihypertensives 60 prospective randomized placebo 60 sorafenib tablets 60 ceftazidime 60 Tekturna HCT 60 TAXUS VI 60 dose clopidogrel 60 doxorubicin docetaxel 60 oral prodrug 60 cobicistat 60 recurrent VTE 60 NNRTIs 60 INVANZ 60 rifapentine 60 treatment regimens 60 TNF antagonists 60 oral ridaforolimus 60 infliximab 60 plasma uric acid 60 olmesartan 60 relapsing MS 60 antiepileptic drug 60 intramuscular injections 60 colorectal liver metastases 60 CK # plasma concentrations 60 ixabepilone 60 AIR CF1 60 GnRH agonist 60 #mg dose [003] 60 ancrod 60 thromboprophylaxis 60 Doxil ® 60 ketoconazole 60 dose escalation study 60 #mg dose [002] 60 NPH insulin 60 OADs 60 oral ibandronate 60 ethambutol 60 cyclophilin inhibitor 60 PEG Intron 60 zalutumumab 60 PEG SN# 60 REVLIMID lenalidomide 60 clevidipine 60 naltrexone SR 60 fluorouracil leucovorin 60 rituximab 60 EVIZON 60 thienopyridines 60 PEGylated interferon beta 1a 60 tiagabine 60 mg simvastatin 60 multicentre randomized 60 epoetin 60 TroVax ® 60 BAY #-# 60 steroid dexamethasone 60 MNTX 60 plus dexamethasone 60 AEGR 60 rituximab Rituxan 60 gout flares 60 PEG PAL 60 randomized placebo controlled 60 microgram kg 60 Cytoxan 60 estramustine 60 valsartan 60 fluorouracil 60 gemcitabine cisplatin 60 nucleoside reverse transcriptase inhibitors 60 topiramate Topamax 60 hyperphenylalaninemia HPA due 60 enfuvirtide 60 4mg/kg 60 angiographic outcomes 60 Rebif ® 60 atorvastatin #mg 60 Pharmacokinetics PK 60 glycopyrrolate 60 IFN beta 60 metformin monotherapy 60 doripenem 60 Baseline characteristics 60 tenofovir DF 60 dexpramipexole 60 prior chemotherapy regimens 60 Laquinimod 60 nucleoside analog 60 clobazam 60 mitoxantrone plus 60 pegylated interferon alfa 2b 60 randomized #:# 60 antiretroviral naïve 60 virologic response 60 latanoprost 59 sotalol 59 grade glioma 59 tranylcypromine 59 XL# SAR# 59 Flu Cy 59 dose ritonavir 59 levetiracetam 59 Cloretazine 59 investigational protease inhibitor 59 tanespimycin 59 subcutaneous insulin 59 intravitreal injection 59 ZYVOX 59 mTOR inhibitors 59 5 Fluorouracil 59 HBeAg positive 59 PRADAXA 59 ROCKET AF 59 FOLFOX6 chemotherapy regimen 59 phase IIb trial 59 SEROQUEL XR 59 prospectively defined 59 albinterferon alfa 2b 59 CAMMS# 59 Hb levels 59 CYPHER R Sirolimus eluting 59 taxane resistant 59 #beta estradiol 59 dose escalation Phase 59 intravenous bisphosphonates 59 adriamycin 59 trastuzumab Herceptin ® 59 antithrombotics 59 Tolerability 59 Zocor simvastatin 59 angiotensin receptor blocker ARB 59 XEPLION R 59 Sustiva efavirenz 59 rabeprazole 59 antiandrogen 59 adecatumumab 59 optimal dosing 59 HBeAg negative patients 59 molecular weight heparins 59 OMS# 59 glulisine 59 MGd 59 entecavir 59 doxorubicin HCl liposome injection 59 mRCC 59 ganetespib 59 oral alendronate 59 bezafibrate 59 Phase III Clinical Trials 59 FROVA 59 tamoxifen therapy 59 diabetic neuropathic pain 59 dose melphalan 59 Phase 2b study 59 T2DM 59 TKI therapy 59 Crestor rosuvastatin 59 clodronate 59 Dapagliflozin 59 MabCampath 59 PEG Interferon lambda 59 EOquin TM phase 59 alpha 2b 59 ritonavir boosting 59 evaluating Xcytrin 59 saquinavir ritonavir 59 methotrexate monotherapy 59 adjunctive ABILIFY 59 SPRYCEL ® 59 blind randomized 59 nonvertebral fractures 59 plus methotrexate 59 lixisenatide 59 oxymorphone ER 59 Epirubicin 59 Omacetaxine mepesuccinate 59 #mg/day [001] 59 deferiprone 59 μg kg 59 Targretin capsules 59 REYATAZ R 59 levosimendan 59 MAS XR 59 cytarabine daunorubicin 59 #mg BID [001] 59 Byetta exenatide 59 refractory NSCLC 59 venlafaxine ER 59 haloperidol Haldol 59 COPAXONE R 59 macrolide antibiotic 59 overlapping toxicities 59 dasatinib Sprycel 59 BRAF inhibitor 59 ug kg 59 pharmacokinetic characteristics 59 exemestane Aromasin 59 anastrozole 59 sulfasalazine 59 peginterferon alpha 2a 59 efavirenz emtricitabine 59 serotonin norepinephrine reuptake inhibitor 59 relapsed SCLC 59 Zileuton 59 progression TTP 59 ribavirin USP 59 alkylating agent 59 lipid lowering therapies 59 DASISION 59 Pafuramidine 59 administered orally 59 GEM OS2 59 PEGASYS ® 59 tenofovir FTC 59 etoposide 59 paclitaxel carboplatin 59 aflibercept 59 valproate 59 randomized 59 VAPRISOL 59 concurrent chemoradiation 59 suppressive therapy 59 maximal dose 59 dose proportional pharmacokinetics 59 hour bronchodilation 59 randomized clinical trials 59 prospective randomized controlled 59 ZACTIMA 59 hA# 59 CTAP# Capsules 59 AZILECT R 59 Isentress raltegravir 59 PegIFN 59 telcagepant 59 lumiracoxib 59 NSTE ACS 59 postoperative chemotherapy 59 RBC folate 59 PRISTIQ 59 infliximab monotherapy 59 inhaled fluticasone 59 hemoglobin A1c levels 59 CAELYX 59 Aflibercept 59 ritonavir boosted lopinavir 59 rhGH 59 CIMZIA ™ 59 radezolid 59 dose escalations 59 rosuvastatin 59 Combination therapy 59 randomized blinded 59 evaluating REVLIMID 59 plus COPEGUS 59 pharmacodynamic parameters 59 thiazide diuretic 59 Insulin PH# 59 cytarabine 59 QD dosing 59 strontium ranelate 59 LCP AtorFen 59 Torisel 59 Gilead Viread 59 lamivudine zidovudine 59 Copegus ® ribavirin 59 rosuvastatin Crestor 59 mg subcutaneous 59 Capesaris 59 thrombolytic agents 59 prednisone prednisolone 59 aldosterone antagonists 59 abacavir 59 symptomatic BPH 59 TORISEL 59 NOXAFIL Oral Suspension 59 cidofovir 59 dual antiplatelet therapy 59 low dose dexamethasone 59 monotherapies 59 investigational oral 59 dose corticosteroids 59 Pharmacokinetic parameters 59 dose escalation phase 59 HZT 59 Mitoxantrone 59 STELARA 59 Doxil 59 mesalamine 59 mg subcutaneously 59 olanzapine Zyprexa 59 anticlotting drugs 59 GW# [003] 59 cisplatin gemcitabine 59 induce remission 59 placebo intravenously 59 Lipitor #mg 59 PRE SURGE 59 zonisamide SR 59 REYATAZ r 59 insulin aspart 59 pregabalin Lyrica 59 Elotuzumab 59 relapsed myeloma 59 CK # administered 59 acarbose 59 TNF alpha inhibitor 59 peginterferon 59 Folfox 59 Lupuzor ™ 59 aminotransferase elevations greater 59 tipranavir ritonavir 59 TTF Therapy 59 tacrolimus 59 ALT flares 59 PREZISTA ritonavir 59 enzastaurin 59 im peramivir 59 hsCRP levels 59 danazol 59 androgen suppression 59 EFFEXOR XR 59 selective modulator 59 PrandiMet TM 59 deferoxamine 59 PEG Intron ® 59 generation purine nucleoside 59 integrase inhibitor 59 bicalutamide 59 INVEGA R 59 lispro 59 metformin hydrochloride 59 Taxol paclitaxel 59 KRAS status 59 REYATAZ ritonavir 59 cabazitaxel 59 angiotensin converting enzyme inhibitor 59 otamixaban 59 Aptivus ® 59 serum calcium levels 59 amphotericin B 59 taxotere 59 allopurinol 59 INVEGA ® SUSTENNA ® 59 #mg [003] 59 6mg 59 SPRYCEL 59 deforolimus 59 hemodialysis patients 59 acyclovir Lauriad R 59 TELCYTA 59 gemcitabine 59 NSABP B 59 hypofractionated 59 ascending dose study 59 quetiapine 59 HCD# [002] 59 Epoetin alfa 59 nadolol 59 intravenously administered 59 Combo Stent 59 HCV protease inhibitors 59 oral anticoagulants 59 trans retinoic acid ATRA 59 amprenavir 59 DMARD 59 non inferiority 59 MMX mesalamine 59 peginesatide 58 Epivir HBV